LCI-699 5mg

CAT: 0628-A14013-5Size: 5 mgDry Ice: NoHazardous: No

1 / 1

CAT#:0628-A14013-5Size:5 mg

Selected

24/48H Stock Items & 2 to 6 Weeks non Stock Items.

Quick Request Actions

CAS Number

928134-65-0

Chemical Information

Osilodrostat

Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice. As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery has not been curative. Osilodrostat is manufactured by Novartis under the brand name Isturisa. It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013. Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. Cushing's disease), and was granted FDA approval and Orphan Drug designation in the US in March 2020 for the same indication.

CAS Number	928134-65-0
PubChem CID	44139752
IUPAC Name	4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile
Molecular Formula	C13H10FN3
Molecular Weight	227.24
XLogP	1.9
Topological Polar Surface Area	41.6
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	1
Heavy Atom Count	17
Formal Charge	0
Complexity	337

SMILES

C1CC2=CN=CN2[C@H]1C3=C(C=C(C=C3)C#N)F

InChI

InChI=1S/C13H10FN3/c14-12-5-9(6-15)1-3-11(12)13-4-2-10-7-16-8-17(10)13/h1,3,5,7-8,13H,2,4H2/t13-/m1/s1

InChIKey

USUZGMWDZDXMDG-CYBMUJFWSA-N

Chemical Structure

2D Structure

CAS: 928134-65-0

CID: 44139752

Formula: C13H10FN3

MW: 227.24

Interactive 3D Structure

Loading 3D structure...

View on PubChem Raw 3D data

Computed Properties

Property	Value
Molecular Weight	227.24
XLogP3	1.9
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	1
Exact Mass	227.08587549
Monoisotopic Mass	227.08587549
Topological Polar Surface Area	41.6 Å²
Heavy Atom Count	17
Formal Charge	0
Complexity	337
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently-Bonded Unit Count	1
Compound Is Canonicalized	Yes

Related Products

Catalog	Name
A14013-2	LCI-699 2mg
A14013-100	LCI-699 (Osilodrostat) 100mg
A14013-10	LCI-699 (Osilodrostat) 10mg
A14013-25	LCI-699 (Osilodrostat) 25mg
A14013-50	LCI-699 (Osilodrostat) 50mg
A14013-1	LCI-699 (Osilodrostat) 1mg
A14013-10mM-D	LCI-699 (Osilodrostat) 10mM * 1mL in DMSO
A14328-5	Sagopilone 5mg
A15933-5	AC710 5mg
A10575-5	Methazolastone 5mg

Alternative Products

Catalog	Name
MBS131645-01	LCI-699
MBS3840152-01	LCI-699 (Osilodrostat)
T80391-01	LCI peptide
HY-173405-01	VVD-699
GTR19276518-01	CRBN ligand-699
532062	L-659,699
MBS8581999-01	STAT5 (pY694/699) Antibody
E11-9014B	CSFR (Ab-699) Antibody
329317-01	Phospho-Stat5 (Y694/699)
abx134597-01	STAT5 (pY694 / 699) Antibody

LCI-699 5mg

Chemical Information

Related Products

Alternative Products

Popular Products